Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIME - botensilimab + balstilimab vs FOLFOX/XELOX + nivolumab in MSI/dMMR esogastric cancer
2023-506291-28-00Phase 3Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of botensilimab and balstilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Centre Léon Bérard. Primary endpoint: Overall survival. Planned start Feb 2024; status: authorised.
02
Drugs
botensilimabbalstilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2023-506291-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506291-28-00.